Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · AdaptHealth (AHCO)

AdaptHealth Q3 revenue rises 1.8% to $820.3 million; full-year guidance maintained

Positive Impact 3 of 5 earnings Written later

AdaptHealth reported third-quarter 2025 results for the period ended September 30, 2025, with net revenue of $820.3 million, up 1.8% from $805.9 million a year earlier, and adjusted EBITDA of $170.1 million, up 3.5%. The company kept its fiscal 2025 guidance unchanged, including net revenue of $3.18 billion to $3.26 billion and adjusted EBITDA of $642 million to $682 million, and reported that net leverage was 2.68x against a 2.50x target.

Key points

  • Q3 net income attributable to AdaptHealth was $24.5 million, compared with $22.9 million a year earlier.
  • Q3 organic revenue growth was 5.1%, the highest since the first quarter of 2024, per the company.
  • Fiscal 2025 guidance maintained: net revenue $3.18 billion to $3.26 billion; free cash flow $170 million to $190 million.
  • Nine-month net income attributable to AdaptHealth was $32.0 million, down from $40.2 million, and nine-month free cash flow was $140.1 million, down from $162.7 million.

The filing

CompanyAdaptHealth (AHCO)
Form8-K, current report
Filed with the SECNov 4, 2025, 7:06 AM ET
Accession number0001628280-25-048527

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.